Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25266430 | 0.83 | CYSLTR2 (0.46) | PPARGCYSLTR2CYSLTR1DHFREGFR | |
| SCHEMBL2273079 | 0.83 | TSHR (0.38) | ALDH1A1CYSLTR2CYSLTR1GRM2PDCD4 | |
| SCHEMBL29028928 | 0.80 | PPARG (0.42) | PPARGCYSLTR2CYSLTR1DHFREGFR | |
| SCHEMBL2803859 | 0.78 | CYSLTR2 (0.41) | PPARGCYSLTR2CYSLTR1DHFREGFR | |
| SCHEMBL7784135 | 0.78 | PPARG (0.40) | PPARGCYSLTR2CYSLTR1DHFREGFR | |
| SCHEMBL11499077 | 0.76 | PPARG (0.38) | PPARGCYSLTR2CYSLTR1HRH3 | |
| SCHEMBL981567 | 0.75 | CYSLTR2 (0.43) | PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL984285 | 0.75 | CYSLTR2 (0.43) | PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL980664 | 0.75 | CYSLTR2 (0.43) | PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL984717 | 0.75 | CYSLTR2 (0.43) | PPARGCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861039-B1 | HYDROGEL COMPOSITIONS | OPHTALMIC CIE (FR) | 2023-11-01 | — | — | EP | disclosed |
| US-20210369911-A1 | HYDROGEL COMPOSITIONS | UNIVERSITÉ DE HAUTE-ALSACE (FR) | 2021-12-02 | — | — | US | disclosed |
| EP-3861039-A1 | HYDROGEL COMPOSITIONS | Ophtalmic Compagnie (FR) | 2021-08-11 | — | — | EP | disclosed |
| EP-3861042-A1 | HYDROGEL COMPOSITIONS | Ophtalmic Compagnie (FR) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070423-A1 | HYDROGEL COMPOSITIONS | OPHTALMIC COMPAGNIE (FR) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020070422-A1 | HYDROGEL COMPOSITIONS | OPHTALMIC COMPAGNIE (FR) | 2020-04-09 | — | — | WO | disclosed |
| US-20120285342-A1 | PRINTING FORM AND PROCESS FOR PREPARING THE PRINTING FORM WITH CURABLE COMPOSITION HAVING BISPHENOL-BASED EPOXY RESIN | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2522508-A2 | Printing form and process for preparing the printing form with curable composition having bisphenol-based epoxy resin | E. I. du Pont de Nemours and Company (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7777033-B2 | Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof | MICRO SCIENCE TECH CO., LTD. (KR) | 2010-08-17 | — | — | US | disclosed |
| US-20080188655-A1 | Monomer With Anti-Microbial Character, Polymer Using The Same, And Manufacturing Method Thereof | MICRO SCIENCE TECH CO., LTD. (KR) | 2008-08-07 | — | — | US | disclosed |
| US-7361719-B2 | Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof | MICRO SCIENCE TECH CO., LTD. (KR) | 2008-04-22 | — | — | US | disclosed |
| US-20050176905-A1 | Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof | MICRO SCIENCE TECH CO., LTD. (KR) | 2005-08-11 | — | — | US | disclosed |
| WO-2003064412-A1 | MONOMER WITH ANTI-MICROBIAL CHARACTER, POLYMER USING THE SAME, AND MANUFACTURING METHOD THEREOF | MICRO SCIENCE TECH CO., LTD. (KR) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188655-A1 | Monomer With Anti-Microbial Character, Polymer Using The Same, And Manufacturing Method Thereof | PCNA, HSF1, TERB1 | ALDH1A1 2231/4885PPARG 2155/4885GLA 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.